Download PDF
Pneumologie 2017; 71(02): 86-95
DOI: 10.1055/s-0042-111522
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Sporadische Lymphangioleiomyomatose (sLAM) und Tuberöse-Sklerose-Komplex (TSC) – Pulmonale Manifestationen

Sporadic Lymphangioleiomyomatosis (sLAM) and Tuberous Sclerosis Complex (TSC) – Pulmonary Manifestations
S. Brakemeier
1   Med. Klinik m. S. Nephrologie, Charité Universitätsmedizin Berlin, Berlin
,
C. Grohé
2   Ev. Lungenklinik – Berlin Buch, Klinik für Pneumologie, Berlin
,
F. Bachmann
1   Med. Klinik m. S. Nephrologie, Charité Universitätsmedizin Berlin, Berlin
,
K. Budde
1   Med. Klinik m. S. Nephrologie, Charité Universitätsmedizin Berlin, Berlin
› Author Affiliations
Further Information

Publication History

eingereicht 20 June 2016

akzeptiert nach Revision 05 July 2016

Publication Date:
01 September 2016 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

LAM ist eine seltene Multisystemerkrankung, die nahezu ausschließlich Frauen im gebärfähigen Alter betrifft. LAM kann in zwei verschiedenen Formen auftreten: erstens als nicht vererbbare sporadische LAM (sLAM) und zweitens als autosomal dominant vererbbare Erkrankung im Rahmen des Tuberöse-Sklerose-Komplexes (TSC). Bei bis zu 50 % der weiblichen TSC-Patienten wird eine Lungenbeteiligung in Form einer Lymphangioleiomyomatose (TSC-LAM) beschrieben, die meist ab einem Alter von 20 – 35 Jahren symptomatisch wird und die zu einer langsam fortschreitenden Verschlechterung der Lungenfunktion von ca. 3 – 11 % der Diffusionskapazität pro Jahr führen kann. Daher sollten alle weiblichen TSC-Patienten ab der Adoleszenz auf pulmonale Manifestationen untersucht werden. (Lungenfunktion, 6-Minuten-Gehtest und HR-CT). Die Wirksamkeit einer Therapie mit mTOR-Inhibitoren wie z. B. Everolimus oder Sirolimus bei verschiedenen Manifestationen von TSC inkl. LAM konnte in den letzten Jahren gezeigt werden. Die systematische Erfassung aller krankheitsrelevanten Manifestationen ermöglicht eine Verbesserung der Prognose und verhindert Komplikationen.

Abstract

Lymphangioleiomyomatosis (LAM) is a rare multi-system disorder affecting predominantly women of childbearing age. The disease entity is divided in sporadic LAM (sLAM) and LAM associated with tuberous sclerosis complex (TSC). In up to 50 % of female TSC-patients pulmonary involvement (TSC-LAM) can be found, with first clinical symptoms usually starting between 25 and 30 years of age. Progressive deterioration of lung function of 3 – 11 % of diffusion capacity per year has been described, that’s why all female TSC patients should be screened for LAM (pulmonary function testing, 6-minute walk test, high-resolution chest CT scan). MTOR inhibitors such as Everolimus or Sirolimus are implemented in the treatment of TSC/LAM and found to control disease burden. Screening for all organ manifestations in TSC is recommended and allows to improve prognosis and to prevent complications in TSC.

Anhang

 

  • Literatur

  • 1 Di Marco F, Terraneo S, Imeri G. et al. Women with TSC: Relationship between clinical, lung function and radiological features in a genotyped population investigated for lymphangioleiomyomatosis. PLoS One 2016; 11: e0155331
    CrossrefPubMedGoogle Scholar
  • 2 Cudzilo CJ, Szczesniak RD, Brody AS. et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013; 144: 578-585
    CrossrefPubMedGoogle Scholar
  • 3 Taveira-DaSilva AM, Moss J. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin Epidemiol 2015; 7: 249-257
    CrossrefPubMedGoogle Scholar
  • 4 Bissler JJ, Kingswood JC, Radzikowska E. et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant 2016; 31: 111-119
    CrossrefPubMedGoogle Scholar
  • 5 Franz DN, Agricola K, Mays M. et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol 2015; 78: 929-938
    CrossrefPubMedGoogle Scholar
  • 6 Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep's clothing. J Clin Invest 2012; 122: 3807-3816
    CrossrefPubMedGoogle Scholar
  • 7 McCormack FX, Inoue Y, Moss J. et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606
    CrossrefPubMedGoogle Scholar
  • 8 Moua T, Olson EJ, Jean HC. et al. Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med 2012; 186: 389-390
    CrossrefPubMedGoogle Scholar
  • 9 Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49: 255-265
    CrossrefPubMedGoogle Scholar
  • 10 Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372: 657-668
    CrossrefPubMedGoogle Scholar
  • 11 Budde K, Gaedeke J. Tuberous Sclerosis Complex–Associated Angiomyolipomas: Focus on mTOR Inhibition. Am J Kidney Dis 2012; 59: 276-283
    CrossrefPubMedGoogle Scholar
  • 12 Osborne JA, Fryer D, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 1991; 615, 125-127
    PubMedGoogle Scholar
  • 13 O'Callaghan FJ, Noakes MJ, Martyn CN. et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 2004; 94: 853-857
    CrossrefPubMedGoogle Scholar
  • 14 Bissler J, Cappell K, Charles H. et al. Rates of interventional procedures in patients with tuberous sclerosis complex-related renal angiomyolipoma. Curr Med Res Opin 2015; 31: 1501-1507
    CrossrefPubMedGoogle Scholar
  • 15 Eijkemans MJ, van der Wal W, Reijnders LJ. et al. Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands. Am J Kidney Dis 2015; 66: 638-645
    CrossrefPubMedGoogle Scholar
  • 16 McCormack FX, Travis WD, Colby TV. et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012; 186: 1210-1212
    CrossrefPubMedGoogle Scholar
  • 17 Tuberous Sclerosis Study Group. Holmes GL, Stafstrom CE. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 2007; 48: 617-630
    CrossrefPubMedGoogle Scholar
  • 18 Joinson C, O'Callaghan FJ, Osborne JP. et al. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 2003; 33: 335-344
    CrossrefPubMedGoogle Scholar
  • 19 Kingswood JC, Bruzzi P, Curatolo P. et al. TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet J Rare Dis 2014; 9: 182
    CrossrefPubMedGoogle Scholar
  • 20 Franz DN, Belousova E, Sparagana S. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132
    CrossrefPubMedGoogle Scholar
  • 21 Kotulska K, Chmielewski D, Borkowska J. et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol 2013; 17: 479-485
    CrossrefPubMedGoogle Scholar
  • 22 de Vries PJ, Whittemore VH, Leclezio L. et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol 2015; 52: 25-35
    CrossrefPubMedGoogle Scholar
  • 23 O'Callaghan FJ, Harris T, Joinson C. et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 2004; 89: 530-533
    CrossrefPubMedGoogle Scholar
  • 24 Bissler JJ, Kingswood JC, Radzikowska E. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-824
    CrossrefPubMedGoogle Scholar
  • 25 Ryu JH, Hartman TE, Torres VE. et al. Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomas. Chest 2012; 141: 163-168
    CrossrefPubMedGoogle Scholar
  • 26 Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008; 358: 199-200
    CrossrefPubMedGoogle Scholar
  • 27 Urban T, Lazor R, Lacronique J. et al. Pulmonary lymphangioleiomyomatosis: A study of 69 patients. Groupe d’Etudes et de Recherche sur les Maladies ‘‘Orphelines’’ Pulmonaires (GERM‘‘O’’P). Medicine (Baltimore) 1999; 78: 321-337
    CrossrefPubMedGoogle Scholar
  • 28 von Ranke FM, Zanetti GE, Silva JL. et al. Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement. Lung 2015; 193: 619-627
    CrossrefPubMedGoogle Scholar
  • 29 Taveira-DaSilva AM, Hathaway O, Stylianou M. et al. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154: 797-805, W-292-293
    CrossrefPubMedGoogle Scholar
  • 30 Ryu JH, Doerr CH, Fisher SD. et al. Chylothorax in lymphangioleiomyomatosis. Chest 2003; 123: 623-627
    CrossrefPubMedGoogle Scholar
  • 31 Almoosa KF, Ryu JH, Mendez J. et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 2006; 129: 1274-1281
    CrossrefPubMedGoogle Scholar
  • 32 National Heart, Lung, and Blood Institute LAM Registry Study Group. Maurer JR, Ryu J, Beck G. et al. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry. J Heart Lung Transplant 2007; 26: 1293-1299
    CrossrefPubMedGoogle Scholar
  • 33 Finlay GA, York B, Karas RH. et al. Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1/2. J Biol Chem 2004; 279: 23114-23122
    CrossrefPubMedGoogle Scholar
  • 34 Radzikowska E, Jaguś P, Sobiecka M. et al. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis. Respir Med 2015; 109: 1469-1475
    CrossrefPubMedGoogle Scholar
  • 35 Xu KF, Zhang P, Tian X. et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med 2013; 107: 263-268
    CrossrefPubMedGoogle Scholar
  • 36 Tiberio D, Franz DN, Phillips JR. Regression of a cardiac rhabdomyoma in a patient receiving everolimus. Pediatrics 2011; 127: e1335-1337
    CrossrefPubMedGoogle Scholar
  • 37 International Tuberous Sclerosis Complex Consensus Group. Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49: 243-254
    CrossrefPubMedGoogle Scholar
  • 38 Yates JRW. Tuberous sclerosis. Eur J Hum Genet 2006; DOI: 10.1038/ sj.ejhg.5201625.
    CrossrefPubMedGoogle Scholar
  • 39 Tyburczy ME, Wang JA, Li S. et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet 2014; 23: 2023-2029
    CrossrefPubMedGoogle Scholar
  • 40 Tyburczy ME, Dies KA, Glass J. et al. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet 2015; 11: e1005637
    CrossrefPubMedGoogle Scholar
  • 41 Jones AC, Shyamsundar MM, Thomas MW. et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64: 1305-1315
    CrossrefPubMedGoogle Scholar
  • 42 Krueger DA, Care MM, Holland K. et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811
    CrossrefPubMedGoogle Scholar
  • 43 Bissler JJ, McCormack FX, Young LR. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151
    CrossrefPubMedGoogle Scholar
  • 44 Wienecke R, Fackler I, Linsenmaier U. et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006; 48: e27-e29
    CrossrefPubMedGoogle Scholar
  • 45 Morton JM, McLean C, Booth SS. et al. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant 2008; 27: 462-465
    CrossrefPubMedGoogle Scholar
  • 46 Franz DN, Leonard J, Tudor C. et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498
    CrossrefPubMedGoogle Scholar
  • 47 Hofbauer GF, Marcollo-Pini A, Corsenca A. et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008; 59: 473-475
    PubMedGoogle Scholar
  • 48 Taillé C, Debray MP, Crestani B. Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann Intern Med 2007; 146: 687-688
    PubMedGoogle Scholar
  • 49 Franz DN, Agricola KD, Tudor CA. et al. Everolimus for Tumor Recurrence After Surgical Resection for Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex. J Child Neurol 2013; 28: 602-607
    CrossrefPubMedGoogle Scholar
  • 50 Jozwiak S, Nabbout R, Curatolo P. Participants of the TSC Consensus Meeting for SEGA and Epilepsy Management. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. Eur J Paediatr Neurol 2013; 17: 348-352
    CrossrefPubMedGoogle Scholar
  • 51 Trelinska J, Dachowska I, Kotulska K. et al. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. Pediatr Blood Cancer 2015; 62: 616-621
    CrossrefPubMedGoogle Scholar
  • 52 Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008; 23: 1238-1239
    CrossrefPubMedGoogle Scholar
  • 53 Muncy J, Butler IJ, Koenig MK. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol 2009; 24: 477
    CrossrefPubMedGoogle Scholar
  • 54 Guo J, Tretiakova MS, Troxell ML. et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol 2014; 38: 1457-1467
    CrossrefPubMedGoogle Scholar
  • 55 Davies DM, de Vries PJ, Johnson SR. et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011; 17: 4071-4081
    CrossrefPubMedGoogle Scholar
  • 56 Sauter M, Sigl J, Schotten KJ. et al. Association of oestrogen-containing contraceptives with pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex – findings from a survey. Eur J Contracept Reprod Health Care 2014; 19: 39-44
    CrossrefPubMedGoogle Scholar
  • 57 Xu KF, Lo BH. Lymphangioleiomyomatosis: differential diagnosis and optimal management. Ther Clin Risk Manag 2014; 10: 691-700
    PubMedGoogle Scholar
  • 58 Kotulska K, Borkowska J, Jozwiak S. Possible prevention of tuberous sclerosis complex lesions. Pediatrics 2013; 132: e239-242
    CrossrefPubMedGoogle Scholar
  • 59 Cai X, Pacheco-Rodriguez G, Haughey M. et al. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis. Chest 2014; 145: 108-112
    CrossrefPubMedGoogle Scholar
  • 60 Lesma E, Chiaramonte E, Ancona S. et al. Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis. Biomed Res Int 2015; 2015: 315240
    PubMedGoogle Scholar
  • 61 Li C, Zhang E, Sun Y. et al. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis. PLoS One 2014; 9: e104809
    CrossrefPubMedGoogle Scholar
  • 62 Atochina-Vasserman EN, Goncharov DA, Volgina AV. et al. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Respir Cell Mol Biol 2013; 49: 704-709
    CrossrefPubMedGoogle Scholar
  • 63 El-Chemaly S, Henske EP. Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev 2014; 23: 30-35
    CrossrefPubMedGoogle Scholar
  • 64 Yeoh ZW, Navaratnam V, Bhatt R. et al. Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance. Orphanet J Rare Dis 2014; 9: 151-153
    CrossrefPubMedGoogle Scholar
  • 65 Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 2014; 28: 126-133
    CrossrefPubMedGoogle Scholar
  • 66 Budde K, Zonnenberg BA, Frost M. et al. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br J Clin Pharmacol 2016; 81: 958-970
    CrossrefPubMedGoogle Scholar
  • 67 Weidman DR, Pole JD, Bouffet E. et al. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Pediatr Blood Cancer 2015; 62: 1754-1760
    CrossrefPubMedGoogle Scholar
  • 68 Braun M, Young J, Reiner CS. et al. Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. PLoS One 2012; 7: e45868
    CrossrefPubMedGoogle Scholar
  • 69 Duerr M, Glander P, Diekmann F. et al. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5: 703-708
    CrossrefPubMedGoogle Scholar
  • 70 Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today 2015; 20: 1243-1249
    CrossrefPubMedGoogle Scholar